Challenger Tells Federal Circuit Patent Wrongly Deemed Nonobvious
WASHINGTON, D.C. — A decision by the Patent Trial and Appeal Board that confirmed the patentability of the rheumatoid arthritis drug Orencia despite findings in the same ruling that a person...To view the full article, register now.
Already a subscriber? Click here to view full article